Idorsia Ltd (IDIA) - Total Liabilities

Latest as of September 2025: CHF1.59 Billion CHF ≈ $2.01 Billion USD

Based on the latest financial reports, Idorsia Ltd (IDIA) has total liabilities worth CHF1.59 Billion CHF (≈ $2.01 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Idorsia Ltd generate cash to assess how effectively this company generates cash.

Idorsia Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Idorsia Ltd's total liabilities have evolved over time, based on quarterly financial data. Check IDIA financial resilience to evaluate the company's liquid asset resilience ratio.

Idorsia Ltd Competitors by Total Liabilities

The table below lists competitors of Idorsia Ltd ranked by their total liabilities.

Company Country Total Liabilities
Sky Gold Limited
NSE:SKYGOLD
India Rs9.05 Billion
Suzhou Alton Electrical & Mechanical Industry Co. Ltd.
SHE:301187
China CN¥2.35 Billion
indie Semiconductor Inc
NASDAQ:INDI
USA $462.15 Million
Shanghai Amarsoft Information & Technolgy Co Ltd
SHE:300380
China CN¥729.22 Million
Zehnder
SW:ZEHN
Switzerland CHF189.35 Million
Hefei Fengle Seed Co Ltd
SHE:000713
China CN¥1.54 Billion
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
Brazil R$1.79 Billion
Contec Medical Systems Co Ltd
SHE:300869
China CN¥1.02 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Idorsia Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Idorsia Ltd worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.40 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.40 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.50 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Idorsia Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Idorsia Ltd (2016–2024)

The table below shows the annual total liabilities of Idorsia Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 CHF1.72 Billion
≈ $2.17 Billion
+16.98%
2023-12-31 CHF1.47 Billion
≈ $1.86 Billion
-6.16%
2022-12-31 CHF1.57 Billion
≈ $1.98 Billion
+13.52%
2021-12-31 CHF1.38 Billion
≈ $1.74 Billion
+62.23%
2020-12-31 CHF849.88 Million
≈ $1.07 Billion
+1.19%
2019-12-31 CHF839.85 Million
≈ $1.06 Billion
+12.11%
2018-12-31 CHF749.14 Million
≈ $947.12 Million
+35.62%
2017-12-31 CHF552.37 Million
≈ $698.34 Million
+35.67%
2016-12-31 CHF407.15 Million
≈ $514.75 Million
--

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology
Market Cap
$1.14 Billion
CHF905.23 Million CHF
Market Cap Rank
#10420 Global
#126 in Switzerland
Share Price
CHF3.68
Change (1 day)
+1.60%
52-Week Range
CHF1.28 - CHF4.70
All Time High
CHF33.62
About

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more